Earnings call Heron Therapeutics reported Q2 2025 net revenues of $37.2M and achieved positive adjusted EBITDA of $1.8M, reversing a loss from the prior year. Demand for Zynrelef and Aponvie grew ...

CARY, N.C., Aug. 8, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that it has rescheduled its release of ...

Heron Therapeutics (HRTX) reported its third-quarter 2025 earnings on November 4, revealing a greater-than-expected loss per share and missing revenue forecasts. The company’s stock reacted negatively ...

Earnings call Heron reported Q2 2025 net revenue of $37.2M and YTD revenue of $76.1M, with adjusted EBITDA turning positive at $7.9M YTD versus a $1.9M loss in 2024. Acute care product demand rose ...

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2025 Earnings Call Transcript August 8, 2025 Heron Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.02 EPS, expectations were $-0.01.